secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001824293-23-000018
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon Pharma reports FY2022 net loss of $7.0M; merges with GRI Bio in all-stock deal
--------------------------------------------------------------------------------

- Net loss of $7.0M for FY2022 vs. $9.3M in FY2021; R&D expenses fell to $1.2M from $5.2M.
- Cash and cash equivalents of $3.8M as of Dec 31, 2022.
- Definitive merger agreement with GRI Bio: all-stock transaction; combined company to operate as GRI Bio, Inc. under ticker 'GRI'.
- Merger expected to close in Q2 2023; focus on NKT cell regulators for inflammatory, fibrotic and autoimmune diseases.
- G&A expenses rose to $5.8M from $4.1M due to evaluation of strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/0001824293-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/val-20230224.htm
  HTML page:      https://secwatch.observer/filing/0001824293-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer